1. Chordia Therapeutics Inc.
  2. News
News
サブ-ナビゲーション
  • Company
  • Science/Pipleline
  • 現在位置:News
  • Investor Relations
  • Career
  • Contact
  • Privacy Policy
  • Term of use
  • Sitemap

News

  • May 15, 2025 Notice Concerning Change of Major Shareholder pdf (249KB)
  • Apr 28, 2025 Notice of Discontinuation of Development of CTX-177 (ONO-7018) pdf (289KB)
  • Apr 25, 2025 Chordia presents new data at the American Association for Cancer Research Annual Meeting 2025 pdf (229KB)
  • Apr 24, 2025 Notice of Release of Transcript of Interim Financial Results Briefing for the Fiscal Year Ending August 31, 2025 pdf (276KB)
  • Apr 11, 2025 For 2nd quarter FY8 2025 Financial Results Presentation pdf (1,132KB)
  • Apr 11, 2025 Non-consolidated Financial Results for the Six Months Ended February 28, 2025 [Japanese GAAP] pdf (442KB)
  • Apr 01, 2025 Presentation of data from our pipeline at the American Association for Cancer Research Annual Meeting 2025 pdf (233KB)
  • Jan 14, 2025 Non-consolidated Financial Results for the Three Months Ended November 30, 2024 [Japanese GAAP] pdf (432KB)
  • Jan 10, 2025 Rogocekib for the treatment of Refractory or Relapsed Acute Myologic Lymphoma(AML) has been granted Orphan Drug Designation (ODD) in the US by the FDA pdf (272KB)
  • Dec 12, 2024 By FISCO Corporation Notice of Distribution of Our Corporate Research Report pdf (267KB)
  • Nov 29, 2024 Corporate Governance Report pdf (659KB)
  • Nov 20, 2024 Announcement of International Nonproprietary Name (INN) for CTX-712 pdf (277KB)
  • Nov 06, 2024 Notice of Convocation of the 7th Annual General Meeting of Shareholders pdf (942KB)
  • Oct 28, 2024 Chordia announces the Release of a Transcript of the Earnings Briefing for the Fiscal Year Ended August 2024 pdf (281KB)
  • Oct 15, 2024 Fiscal year ended August 2024 Financial Results Presentation pdf (1,465KB)
  • Oct 11, 2024 Non-consolidated Financial Results for the Fiscal Year Ended August 31, 2024 [Japanese GAAP] pdf (538KB)
  • Oct 11, 2024 Chordia to Present Results of Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2024 The 86th Annual Meeting of the Japanese Society of Hematolog pdf (283KB)
  • Oct 02, 2024 Chordia was nominated as a finalist of the Informa Pharma Intelligence Awards Japan 2024 pdf (405KB)
  • Oct 01, 2024 Announcement of Presentation on Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 86th Annual Meeting of the Japanese Society of Hematology pdf (281KB)
  • Jul 23, 2024 Chordia wins the Minister of Education, Culture, Sports, Science and Technology Award at the Japan Startup Awards 2024. pdf (610KB)
  • Jul 16, 2024 Non-consolidated Financial Results for the Nine Months Ended May 31, 2024 [Japanese GAAP] pdf (348KB)
  • Jun 14, 2024 Notice of Listing on the Growth Market of the Tokyo Stock Exchange pdf (522KB)
  • Jun 07, 2024 CSO Daisuke Morishita to Speak at the 28th Annua Meeting of Japanese Association for Molecular Target Therapy of Cancer pdf (280KB)
  • Apr 17, 2024 Joint presentation about CDK12 at the 76th Annual Meeting of the Japanese Society of Obstetrics and Gynecology pdf (289KB)
  • Apr 06, 2024 Chordia Presented at the American Association for Cancer Research Annual Meeting 2024 pdf (304KB)
  • Mar 14, 2024 Presentation at 3rd regional symposium on Myelodysplastic syndrome pdf (261KB)
  • Mar 06, 2024 Presentation of data from our pipeline at the American Association for Cancer Research Annual Meeting 2024 pdf (300KB)
  • Feb 15, 2024 CSO Daisuke Morishita receives the Minister of State for Science and Technology Policy Award at the 6th Japan Open Innovation Prize
  • Feb 14, 2024 Chordia CEO to Speak at the Japan Healthcare Venture Summit 2023 Symposium pdf (269KB)
  • Jan 29, 2024 Chordia nominated for the 6th Japan Open Innovation Prize pdf (266KB)
  • Nov 28, 2023 Published 6th Financial Report pdf (300KB)
  • Nov 20, 2023 Chordia Announces Completion of Patient Enrollment in the Phase 1 Study for Solid Tumors and Hematologic Malignancies in Japan pdf (385KB)
  • Oct 19, 2023 Chordia named "Financing Deal of the Year." at the Informa Pharma Intelligence Awards Japan 2023 pdf (355KB)
  • Oct 18, 2023 Chordia named “Judges' Special Award” at Japan Healthcare Venture Summit 2023 pdf (269KB)
  • Oct 18, 2023 Abstract of the summary presentation of the US Phase 1/2 clinical trial of CTX-712 has been accepted at the 65th ASH pdf (293KB)
  • Oct 01, 2023 Yasushi Tanoue appointed Chief Medical Officer (CMO) pdf (274KB)
  • Sep 15, 2023 Selected for the latest edition of "100 Amazing Venture Businesses" in 2023 pdf (184KB)
  • Sep 15, 2023 Nominated as a finalist of the Informa Pharma Intelligence Awards Japan 2023 pdf (267KB)
  • Jun 01, 2023 Dosing of CLK Inhibitor CTX-712 Starts in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome in the U.S. pdf (299KB)
  • May 17, 2023 Fujitsu, Kyoto University, and Chordia Therapeutics Launch AI Trials to Discover Biomarkers for New Cancer Drugs pdf (147KB)
  • Feb 17, 2023 Initiated Phase 1/2 Study of CTX-712, a CLK Inhibitor, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome in the U.S. pdf (301KB)
  • Feb 16, 2023 Receives Development Milestone Payment of CTX-177 (ONO-7018), a MALT1 Inhibitor, According to License Agreement with Ono Pharmaceutical pdf (238KB)
  • Dec 12, 2022 Announces Interim Results of CLK Inhibitor CTX-712 and MALT-1 Inhibitor CTX-177 at the 2022 ASH Annual Meeting. pdf (284KB)
  • Nov 21, 2022 Published 5th Financial Report pdf (496KB)
  • Oct 03, 2022 Chordia Therapeutics Director and Statutory Auditor Appointments pdf (263KB)
  • Sep 08, 2022 Chordia Named “Ministry of Education, Culture, Sports, Science and Technology (MEXT) Award” at Academic Startups 2022 pdf (270KB)
  • Aug 29, 2022 Chordia’s Licensee Ono Pharmaceutical Co., Ltd. Initiated a Phase 1 Study of ONO-7018 (CTX-177), a MALT1 Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia in the U.S. pdf (281KB)
  • Jun 07, 2022 Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting pdf (304KB)
  • Jun 07, 2022 Concludes Basic Agreement on Collaboration with Shionogi Pharma Co., Ltd. pdf (216KB)
  • May 19, 2022 Concludes Basic Agreement on Business Tie Up with MEDIPAL HOLDINGS CORPORATION pdf (232KB)
  • May 19, 2022 Raises Approximately 4 Billion JPY in Series C Financing, Achieving a Cumulative Total of Approximately 8.2 Billion JPY pdf (215KB)
  • May 16, 2022 Featured as a Cover Story in Startup City Magazine’s “Top 10 Japanese Startups 2022” pdf (2,325KB)
  • Apr 07, 2022 Nominated as a Finalist of the Informa Pharma Intelligence Awards Japan 2022 pdf (302KB)
  • Dec 03, 2021 Published 4th financial report pdf (660KB)
  • Sep 24, 2021 Assignment of Statutory Auditor pdf (92KB)
  • Mar 03, 2021 Interview with CEO Miyake Published in Scrip
  • Feb 04, 2021 Interview with CSO Morishita Published in AnswersNews
  • Dec 15, 2020 Notice of License Agreement pdf (121KB)
  • Oct 25, 2019 Chordia Therapeutics Announced the Appointment of CMO & CSO pdf (181KB)
  • Mar 29, 2019 Chordia Therapeutics Raises Around $27 Million in Series B Financing pdf (212KB)
  • Jan 10, 2019 Published Our Article in Forbes JAPAN
  • Nov 30, 2017 Chordia Therapeutics Raises Around $11 Million in Series A Financing pdf (562KB)
  • Nov 22, 2017 Launch of Chordia Therapeutics pdf (562KB)

VIEW ALL

ページの先頭へ
ページの先頭へ
  • footer-content
  • menu
  • gnavi-box